Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Buys 2,500 Shares

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel acquired 2,500 shares of the firm's stock in a transaction on Friday, January 10th. The shares were acquired at an average price of $12.51 per share, with a total value of $31,275.00. Following the completion of the transaction, the chief executive officer now directly owns 5,552,502 shares in the company, valued at approximately $69,461,800.02. This trade represents a 0.05 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Snehal Patel also recently made the following trade(s):

• On Tuesday, January 7th, Snehal Patel acquired 1,800 shares of Greenwich LifeSciences stock. The stock was bought at an average price of $13.75 per share, for a total transaction of $24,750.00.
• On Thursday, January 2nd, Snehal Patel bought 2,000 shares of Greenwich LifeSciences stock. The shares were bought at an average cost of $11.97 per share, with a total value of $23,940.00.
• On Monday, December 30th, Snehal Patel purchased 3,200 shares of Greenwich LifeSciences stock. The stock was bought at an average cost of $11.12 per share, for a total transaction of $35,584.00.

Greenwich LifeSciences Price Performance

GLSI traded down $0.12 during trading on Monday, reaching $12.26. 92,447 shares of the stock traded hands, compared to its average volume of 56,850. The stock's 50-day simple moving average is $13.11 and its two-hundred day simple moving average is $14.04. Greenwich LifeSciences, Inc. has a fifty-two week low of $8.00 and a fifty-two week high of $21.44. The stock has a market cap of $161.16 million, a price-to-earnings ratio of -15.32 and a beta of 1.66.

Institutional Investors Weigh In On Greenwich LifeSciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. State Street Corp increased its holdings in Greenwich LifeSciences by 4.4% in the third quarter. State Street Corp now owns 71,408 shares of the company's stock worth $1,026,000 after buying an additional 3,005 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Greenwich LifeSciences by 4.6% during the 3rd quarter. Geode Capital Management LLC now owns 133,550 shares of the company's stock worth $1,919,000 after purchasing an additional 5,861 shares during the last quarter. Barclays PLC raised its holdings in shares of Greenwich LifeSciences by 323.3% during the 3rd quarter. Barclays PLC now owns 8,560 shares of the company's stock valued at $123,000 after purchasing an additional 6,538 shares in the last quarter. Rhumbline Advisers bought a new position in shares of Greenwich LifeSciences during the 2nd quarter valued at $117,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Greenwich LifeSciences in the 2nd quarter valued at $264,000. 4.16% of the stock is owned by hedge funds and other institutional investors.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.